Identification of drugs associated with reduced severity of COVID-19: A case-control study in a large population

Ariel Israel, M.D., Ph.D.¹ (e-mail: dr.ariel.israel@gmail.com, 0000-0003-4389-8896)
Alejandro A. Schäffer, Ph.D.³ (e-mail: alejandro.schaffer@nih.gov, 0000-0002-2147-8033)
Assi Cicurel, M.D., M.B.A.^{1,2} (e-mail: assi@docurel.net)
Ilan Feldhamer, M.A.¹ (e-mail: feldi3@gmail.com)
Ameer Tal, M.Sc.¹ (e-mail: ameerta@clalit.org.il)
Kuoyuan Cheng, M.S.³ (e-mail: kuoyuan.cheng@nih.gov, 0000-0001-8118-5243)
Sanju Sinha, B.Tech.³ (e-mail: sanju.sinha@nih.gov, 0000-0002-2688-0603)
Eyal Schiff, MD⁴ (e-mail: eyal.schiff1957@gmail.com)
Gil Lavie, M.D., M.H.A., M.B.A.^{1,5} # (e-mail : gillav76@gmail.com)
Eytan Ruppin, M.D., Ph.D.³ # (e-mail: eytan.ruppin@nih.gov, 0000-0002-7862-3940)

Authors Affiliations:

¹ Division of Planning and Strategy, Clalit Health Services, Tel Aviv 62098, Israel
² Clalit Health Services, Southern District and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel
³ Cancer Data Science Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 20892
⁴ Sheba Medical Center, Tel-Aviv University, Ramat Gan 52621, Israel
⁵ Ruth and Bruce Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa 3109601, Israel

Equal contribution last authors

Correspondence to:

Ariel Israel, MD, PhD Department of Research and Data, Division of Planning and Strategy Clalit Health Services 101 Arlozorov Street, Tel Aviv 62098, Israel Telephone: +972-3-3948160 Email: <u>dr.ariel.israel@gmail.com</u>

Abstract

Background

Until COVID-19 drugs specifically developed to treat COVID-19 become more widely accessible, it is crucial to identify whether existing medications have a protective effect against severe disease. Towards this objective, we conducted a large population study in Clalit Health Services (CHS), the largest healthcare provider in Israel, insuring over 4.7 million members.

Methods

Two case-control matched cohorts were assembled to assess which medications, acquired in the last month, decreased the risk of COVID-19 hospitalization. Case patients were adults aged 18-95 hospitalized for COVID-19. In the first cohort, five control patients, from the general population, were matched to each case (n=6202); in the second cohort, two non-hospitalized SARS-CoV-2 positive control patients were matched to each case (n=6919). The outcome measures for a medication were: odds ratio (OR) for hospitalization, 95% confidence interval (CI), and the p-value, using Fisher's exact test. False discovery rate was used to adjust for multiple testing.

Results

Medications associated with most significantly reduced odds for COVID-19 hospitalization include: ubiquinone (OR=0.185, 95% CI (0.058 to 0.458), p<0.001), ezetimibe (OR=0.488, 95% CI ((0.377 to 0.622)), p<0.001), rosuvastatin (OR=0.673, 95% CI (0.596 to 0.758), p<0.001), flecainide (OR=0.301, 95% CI (0.118 to 0.641), p<0.001), and vitamin D (OR=0.869, 95% CI (0.792 to 0.954), p<0.003). Remarkably, acquisition of artificial tears, eye care wipes, and several ophthalmological products were also associated with decreased risk for hospitalization.

Conclusions

Ubiquinone, ezetimibe and rosuvastatin, all related to the cholesterol synthesis pathway were associated with reduced hospitalization risk. These findings point to a promising protective effect which should be further investigated in controlled, prospective studies.

Funding

This research was supported in part by the Intramural Research Program of the National Institutes of Health, NCI.

Introduction

SARS-Cov-2 is a new single-stranded RNA virus, which was first identified in December 2019, and has rapidly spread into a global pandemic of primarily respiratory illness designated as Coronavirus Disease 2019 (COVID-19). This disease is associated with significant mortality, particularly among elderly or overweight individuals, raising considerable concerns for public health. Until a vaccine or specifically designed therapies are available, it is urgent to identify whether existing medications have protective effects against COVID-19 complications using available real-world data. With this aim, we performed a case-control study on electronic health records (EHRs) from Clalit Health Services (CHS), the largest healthcare provider in Israel.

Methods

Participants and Data Sources

We collected data from the Clalit Health Services (CHS) data warehouse on adult patients aged 18 to 95 years, who tested positive for SARS-CoV-2 from the beginning of the pandemic through November 30, 2020, and were admitted for hospitalization through December 31, 2020. Each patient was assigned an index date, which is the first date at which a positive RT-PCR test for SARS-CoV-2 was collected for the patient. Patients' demographic characteristics were extracted, along with existing comorbidities, clinical characteristics including BMI, and estimated glomerular filtration rate (eGFR) at the baseline, defined as of February 2020. In addition, the list of drugs or products acquired by each patient in CHS pharmacies was collected for the month preceding the index date, defined as the 35 days prior to this date.

Reliable identification of medications procured for a given month is enabled by the fact that in CHS, distinct prescriptions are issued for each calendar month. When medications are provided in advance for multiple months, the date at which the prescription for each month of treatment begins is recorded.

This study has been approved by the CHS Institutional Review Board (IRB) with a waiver of informed consent, approval number: COM-0046-20. Patient data that could identify participants were removed prior to the statistical analyses in accordance to the protocol approved by the CHS IRB.

Software

Patients' data were extracted and processed from CHS data-warehouse using programs developed in house in Python and SQL.

Case-control Design and Matching

Hospitalized COVID-19 patients were assigned to two distinct case-control cohorts, which differ in the way control individuals were selected. In *cohort 1*, control patients were chosen among the general population of CHS members. Since controls can be selected from among millions of individuals, five controls were selected to match each case (5:1), with comprehensively matched baseline attributes, including age, gender, BMI category, socio-economic and smoking status, chronic kidney disease (CKD) stage for patients with renal impairment, and main comorbidities diagnoses (hypertension, diabetes, chronic kidney disease (CKD), congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), malignancy, ischemic heart disease). For the matching procedure, patients with undocumented BMI were considered as having a normal BMI, unless an obesity diagnosis was present. Each control was assigned the same index date as the matched case, provided that the patient was still alive and a member of CHS at this date. EHR data were collected for controls using the same procedure described for cases. *Cohort 1* is designed to identify drugs that affect the overall risk for hospitalization for COVID-19, where the effect could combine a decreased risk of detectable infection, and a decreased risk for hospitalization once infected.

In *cohort 2*, control patients were chosen among patients who had a positive test for SARS-CoV-2 but had not been hospitalized as of December 31, 2020. Given the smaller size of the pool from which controls can be drawn, only two controls were matched for each case patient. Attributes that were matched were the age, gender, smoking status, Adjusted Clinical Groups® (ACG) measure of comorbidity (Shadmi et al., 2011) and presence/absence of an obesity diagnosis. The index date taken was the date of the first positive SARS-CoV-2 PCR test both for cases and for controls. *Cohort 2* is more specifically suited to identify drugs that are associated with a decreased risk for COVID-19 hospitalization in patients who had a proven infection with the virus. In both cohorts, there were a minority of case individuals for which enough matching controls could not be found; these cases were not included in their respective cohorts. Patients who were pregnant since February 2020 were also excluded.

Outcome Measures

In each cohort, and for each medication anatomical therapeutic chemical (ATC) class, the odds ratio for hospitalization was computed, comparing the number of patients who acquired a medication belonging to the class in the 35 days preceding the index date, in the case and the control groups.

Statistical analysis

Odds ratios for hospitalization for drugs acquired in the case versus control groups and statistical significance were assessed by Fisher's exact test. Correction for multiple testing was performed using the Benjamini-Hochberg procedure (Benjamini and Hochberg, 1995), which gives an estimation of

the false discovery rate (FDR) in the list. Statistical analyses were performed in R statistical software version 3.6 (R Foundation for statistical computing).

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. AI, IF and AT had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results

Through December 31, 2020, 10,295 adult patients between the ages of 18 and 95 had a recorded COVID-19 related hospitalization in the CHS database. The matching procedure was able to identify control individuals from the general population in ratio 5:1 for 6,530 patients in the first cohort, and control patients in ratio 2:1 for 6,953 SARS-CoV-2 positive individuals in the second cohort. The characteristics of the matched populations are shown in **Table 1**.

In each of the two cohorts, we counted the number of patients from each group who acquired drugs and other medical products from each Anatomical Therapeutic Chemical (ATC) class and computed the odds ratios and p-values using Fisher's test. The distribution of odds ratios for drugs for which the p-value was statistically significant (p<0.05) is shown in **Figure 1**. The odds ratios for most drugs are neutral or associated with an increased risk of COVID-19 hospitalization. Only a small number of items are associated with decreased risk: 1.15% in cohort 1, and 1.75% in cohort 2.

Table 2 presents the list of drugs and products that were found to be negatively associated with COVID-19 hospitalization in a statistically significant manner in cohort 1 (A) and in cohort 2 (B). We display items for which the p-value is below 0.05, and for which the false discovery rate (FDR) is less than 0.20, meaning that at least 80% of the items in the displayed list are expected to be true positives. Items are sorted in decreasing order of significance.

The top ranked medications by significance in *cohort 1* were rosuvastatin (odds ratio (OR)=0.673, 95% confidence interval (CI) 0.596 to 0.758), ezetimibe (OR=0.488, CI 0.377 to 0.622), and ubiquinone (OR=0.181, CI 0.065 to 0.403); these same three medications were also in the top 5 by significance of *cohort 2*: rosuvastatin (OR=0.732, CI 0.643 to 0.83), ezetimibe (OR=0.602; CI 0.471 to 0.764), and ubiquinone (OR=0.181, CI 0.065 to 0.403). It

is remarkable that these three drugs act on the cholesterol and ubiquinone synthesis pathways, which both stem from the mevalonate pathway (Buhaescu and Izzedine, 2007); the intermediate product at the branch point is farnesyl polyphosphate (FPP) (**Figure 2**). Rosuvastatin and other statins specifically inhibit he enzyme HMG-CoA reductase. Ubiquinone is a food supplement available over the counter (OTC), which is often recommended to patients prone to muscular pain and receiving a statin treatment(Qu et al., 2018). Risedronate, which also acts on this pathway, and is commonly used to prevent osteoporosis, by blocking the enzyme FPP synthase is also identified by both cohorts, and is ranked 4th by significance in *cohort 2* (OR=0.567; CI 0.400 to 0.789), and 13th in *cohort 1* (OR=0.705; CI 0.522 to 0.935).

Other medications that fulfilled the stringent criteria of being identified by both cohorts with a false discovery rate of 80% include the pneumococcal conjugate vaccine (OR=0.476, CI 0.288 to 0.746 in *cohort 1*; 0.602, CI 0.245 to 0.685 in *cohort 2*), magnesium citrate (OR=0.652, CI 0.433 to 0.952 in *cohort 1*; 0.609, CI 0.399 to 0.908 in *cohort 2*), vitamin D (OR=0.898, CI 0.821 to 0.980 in *cohort 1*; 0.869, CI 0.792 to 0.954 in *cohort 2*), flecainide (OR=0.301, CI 0.118 to 0.641 in *cohort 1*; 0.325, CI 0.123 to 0.729 in *cohort 2*), escitalopram (OR=0.824, CI 0.708 to 0.955 in *cohort 1*; 0.766, CI 0.654 to 0.894 in *cohort 2*), cilazapril (OR=0.554, CI 0.315 to 0.918 in *cohort 1*; 0.468, CI 0.247 to 0.831 in *cohort 2*), ramipril combined with hydrochlorothiazide (OR=0.734, CI 0.603 to 0.887 in *cohort 1*; 0.702, CI 0.565 to 0.869 in *cohort 2*), and sitagliptin combined with metformin (OR=0.802, CI 0.696 to 0.922 in *cohort 1*; 0.826, CI 0.704 to 0.967 in *cohort 2*). Sitagliptin alone is also significant in *cohort 1* (OR=0.658, CI 0.443 to 0.950).

In addition, we observe interesting patterns in *cohort 2*, which is designed to identify drugs associated with decreased hospitalization risk in SARS-CoV-2 positive patients: several vitamin or mineral supplementation items appear to have a protective effect, in addition to vitamin D and magnesium citrate, which were identified by both cohorts: vitamin B12 combinations (OR=0.618, CI 0399 to 0.934), multivitamins for ocular use (OR=0.616; 0.376 to 0.976), and calcium-zinc combinations (OR=0.000, CI 0.000 to 0.892).

Several ophthalmic items also appear to be associated with significantly decreased odds for hospitalization, including artificial tears, hydroxypropylmethylcellulose-based (OR=0.657, CI 0.490 to 0.871) or hyaluronic acid based (OR=0.322, CI 0.098 to 0.836); decreased odds ratio are also found for items that may act as a physical barrier to the eye: eye care wipes,

which are sterile wipes sold to clean the eyes (OR=0.285, CI 0.054 to 0.956), a retinol based ointment used to treat cornea abrasion (OR=0.285, CI 0.054 to 0.956), and timolol drops used to treat glaucoma (OR=0.570, CI 0.328 to 0.949).

Also associated with decreased odds for hospitalization are several drugs based on an ACE inhibitor or an angiotensin receptor blocker (ARB), sometimes in combination with another compound. In addition to cilazapril and ramipril-hydrochlorothiazide that were highly ranked in both cohorts, *cohort 1* identifies candesartan (OR=0.718, CI 0.544 to 0.934), and *cohort 2*, identifies valsartan with amlodipine (OR=0.821, CI 0.698 to 0.963), and losartan with hydrochlorothiazide (OR=0.783, CI 0.630 to 0.969).

Remarkably, several drugs acting on receptors to neurotransmitters also appear to decrease hospitalization risk: rizatriptan (OR=0.118, CI 0.003 to 0.750), bupropion (OR=0.399, CI 0.136 to 0.976), and methylphenidate (OR=0.444, CI 0.178 to 0.972).

Discussion

In this large-scale retrospective study, we identified several drugs and products that are significantly associated with reduced odds for COVID-19 hospitalization, both in the general population, and in patients with laboratory proven SARS-CoV-2 infection. Several other research groups have recognized the potential for EHRs to enable large-scale studies in COVID-19 and the challenges of this sort of retrospective research are reviewed in (Dagliati et al., 2021; Sudat et al., 2021). To give a few examples, EHRs have also been used to predict: i) COVID-19 mortality based on pre-existing conditions (Estiri et al., 2021; Osborne et al., 2020), ii) early diagnosis of COVID-19 based on clinical notes (Wagner et al., 2020) and iii) eligibility of COVID-19 patients for clinical trials by matching trial criteria with patient records (Kim et al., 2021).

Major strengths of our study include: (i) the large sample of hospitalized COVID-19 patients, (ii) the ability to collect comprehensive data about individual demographic and comorbidity characteristics and to build matched case and control populations, (iii) the ability to track hospitalizations and disease severity, owing to a central database established by the Israeli Ministry of Health and, (iv) the capacity to track which drugs and products have been acquired by patients in the period that have preceded SARS-CoV-2 infection, owing to comprehensive digital systems integration in CHS.

Another strength is the dual cohort design, with control individuals taken from the general population in the first cohort and from individuals positive for SARS-CoV-2 in the second cohort, with each using different matching criteria, mitigates potential bias that could affect each cohort. The two cohorts allowed us to evaluate the protective effect of drugs that act either by reducing the initial risk of infection, or by reducing the risk of hospitalization in those infected. Analyses are based on items procured in the 35 days before the initial positive test. This window was chosen in accordance with the monthly renewal of prescription policy in place in CHS.

Limitations of this study are related to it being observational in nature. Best efforts were made to use matching so that patients in case and controls are similar regarding most of the known factors for disease severity, and notably, age, obesity, smoking, and baseline comorbidity. We aimed to get a sensible tradeoff between controlling for confounding factors by rigorous matching and keeping enough patients so that cohorts are representative of the general population. Our analysis is based on medication acquisition in pharmacies and does not ascertain that medications purchased were used. Notably, some of the drugs associated with a protective effect may have been stopped during patient's hospitalization so that our analysis may have underestimated the full achievable benefits for some of the drugs. Conversely, since drugs tested here were acquired before patients were positive for SARS-CoV-2, the protective effect of some of the drugs may be fully attained only when treatment is started before or early in the infection.

Bearing these strengths and potential limitations in mind, our analyses seem to indicate several viral vulnerability points, which can potentially be exploited to effectively reduce disease severity with drugs that are already available. The drugs identified as protective include ubiquinone, which is a food supplement with a very good safety profile that does not even require a prescription in our health system, and rosuvastatin and ezetimibe, two drugs prescribed routinely to reduce cholesterol and that have a very good safety profile. These findings are in line with previous reports that RNA viruses need cholesterol to enter cells, for virion assembly, and to maintain structural stability (Aizaki et al., 2008; Bajimaya et al., 2017; Rossman et al., 2010; Sun and Whittaker, 2003), and that prescribing statins may protect against infection with RNA viruses such as members of family *Flaviviridae*, including Dengue virus, Zika virus, and West Nile virus (Gower and Graham, 2001; Osuna-Ramos et al., 2018; Whitehorn et al., 2015). The involvement of the cholesterol/ubiquinone pathway is further confirmed by the fact that risedronic acid, a drug acting on the enzyme

farnesyl pyrophoshate synthase (Tsoumpra et al., 2015) (**Figure 2**) which catalyzes the production of FPP from which the cholesterol and the ubiquinone synthesis pathways split (Buhaescu and Izzedine, 2007), is identified as protective as well, even though it is prescribed for osteoporosis regardless of the presence of hypercholesterolemia.

Taken together, our findings lend (albeit indirect) support to the possibility that SARS-CoV2 hijacks the cholesterol synthesis pathway, possibly to boost production of the cellular cholesterol it needs as an RNA virus. The fact that ubiquinone protects against severe disease, suggests that SARS-CoV2 may tilt the mevalonate pathway towards cholesterol synthesis and away from ubiquinone synthesis. Such a pathway imbalance would ultimately result in deficiency of ubiquinone that could lead to cell death unless counteracted by ubiquinone supplementation.

It is remarkable that the protective effect of anti-cholesterol drugs was observed mostly for rosuvastatin - and in *cohort 1* for pravastatin - but not for other statins. Rosuvastatin was found to significantly increase 25-OH vitamin D levels in the blood (Yavuz et al., 2009), much more than what could be observed with other statins. Yavuz et al. (Yavuz and Ertugrul, 2012) suggested that the increase in 25-OH vitamin D observed following rosuvastatin treatment could be mediated by the Niemann-Pick C1 Like 1 (NPC1L1) membrane transporter that is involved in intestinal absorption of vitamin D. Interestingly, the NPC1L1 membrane transporter is also the target of ezetimibe, identified by our study to decrease significantly the hospitalization risk of COVID-19 patients.

In both cohorts, we observed a significant decrease of the odds for hospitalization for COVID-19 patients treated with either vitamin D or magnesium citrate. Vitamin D deficiency has been shown to be associated with increased risk for COVID-19 in multiple studies (Israel et al., 2020; Merzon et al., 2020). Magnesium is needed for vitamin D activation (Uwitonze and Razzaque, 2018) and its levels in drinking water in Israel are low, as water is produced in great part through desalination of sea water (Koren et al., 2017). The decreased hospitalization rate revealed here for patients taking magnesium supplementation may suggest a role for supplementation of this element along with vitamin D. Hospitalization risk was also found to be decreased in patients taking vitamin B12 and calcium-zinc, as identified by other studies (Ragan et al., 2020; Trasino, 2020; Wessels et al., 2020).

Another medication that was associated with decreased odds for hospitalization is flecainide, an antiarrhythmic drug that blocks sodium channels in the heart, and inhibits ryanodine

receptor 2 (RyR2), a major regulator of sarcoplasmic release of stored calcium ions. It may prevent apoptosis by release of calcium from the ER once the cell mitochondria cease to function. An expert review recommended that patients with arrhythmia who get COVID-19 should continue flecainide treatment if already prescribed (Wu et al., 2020). In our study, the protective effect observed in both cohorts is even more marked for severe patients, suggesting that this drug, which can be given intravenously (Antonelli et al., 2006), could be administered to patients in respiratory distress, if the protective effect is confirmed in clinical trials.

Several drugs acting as ACE inhibitors or Angiotensin receptor blockers (ARBs) appeared to slightly decrease the odds for hospitalization, either alone or in combination (cilazapril, ramipril-hydrochlorothiazide, losartan-hydrochlorothiazide, valsartan amlodipine). These results are consistent with ACE and ARBs treated patients shown to not have an increased risk for COVID-19 (Morales et al., 2020), and there is therefore no reason to discontinue these medications to decrease COVID-19 risk. Our findings also confirm and substantially extend recent EHR-based findings about the favorable association between metformin use and COVID-19 outcomes (Bramante et al., 2021).

In addition, several drugs acting on synapses (escitalopram, bupropion, mirabegron, and timolol) were associated with decreased risk of hospitalization. This is consistent with SARS-CoV-2 invading neuronal cells (Iroegbu et al., 2020; Meinhardt et al., 2020; Song et al., 2021), as manifest by symptoms of loss of smell and taste, where it may spread throughout the nervous system across synapses. Decreased neurotransmitter internalization may therefore reduce the infectious potential of the virus.

Interestingly, items that could improve the physical barrier of the eye surface were among the top items decreasing odds of hospitalization, including eye wipes, artificial tears, and eye ointments. Interestingly, the protective effect for these items was observed foremost among patients from *cohort 2* in which controls are already SARS-CoV-2 positive. This suggests that these barrier items could not only protect against the initial risk of infection, but, notably, also reduce disease severity in patients already infected. The beneficial effect observed here for many different ophthalmologic preparations, raises the possibility that autoinoculation of the virus to the eyes, prevented by these items, has a role in the virulence of SARS-CoV-2. The possibility that invasion of the central nervous system (CNS) by the virus through the eyes could increase the risk of COVID-19 complications is also supported by the fact that

10

eyeglass wearers were shown previously to be at decreased risk for COVID-19 hospitalization (Zeng et al., 2020). Until the meaning of these findings is fully understood, it may be helpful to advise COVID-19 patients to avoid touching their eyes in order to reduce the risk of complications.

In conclusion, this study shows apparently protective effects for several medications and dietary supplements, such as rosuvastatin, ezetimibe, ubiquinone, risedronate, vitamin D, and magnesium. We suggest to further investigate these, and other products identified by this study, in prospective trials aimed to reduce disease severity in COVID-19 patients. In the meantime, we believe that the observed protective effects of these drugs provide important evidence supporting their safe continuation for COVID-19 patients.

Contributors

All authors provided final approval to publish. AI, IF and AT had access to the raw data. AI designed the study. AI, AAS, AC, IF, AT, KC, SS, ES, GL and ER contributed to data analysis and interpretation. AI, AAS, ER and GL contributed to the drafting of the article. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. AI is the guarantor.

Competing interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. The authors declare no competing interests. AI, AC, IF, AT, and GL are employees of Clalit Health Services. All authors declare that they have no other relationships or activities that could appear to have influenced the submitted work.

References

- Aizaki H, Morikawa K, Fukasawa M, Hara H, Inoue Y, Tani H, Saito K, Nishijima M, Hanada K, Matsuura Y, Lai MMC, Miyamura T, Wakita T, Suzuki T. 2008. Critical Role of Virion-Associated Cholesterol and Sphingolipid in Hepatitis C Virus Infection. J Virol 82:5715–5724. doi:10.1128/jvi.02530-07
- Antonelli D, Feldman A, Freedberg NA, Darawsha A, Rosenfeld T. 2006. Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the Emergency Room. *Harefuah* **145**:342–344.
- Bajimaya S, Hayashi T, Frankl T, Bryk P, Ward B, Takimoto T. 2017. Cholesterol reducing agents inhibit assembly of type I parainfluenza viruses. *Virology* 501:127–135. doi:10.1016/j.virol.2016.11.011
- Benjamini Y, Hochberg Y. 1995. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B* **57**:289–300. doi:10.1111/j.2517-6161.1995.tb02031.x
- Bramante CT, Buse J, Tamaritz L, Palacio A, Cohen K, Vojta D, Liebovitz D, Mitchell N, Nicklas J, Lingvay I, Clark JM, Aronne LJ, Anderson E, Usher M, Demmer R, Melton GB, Ingraham N, Tignanelli CJ. 2021. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. *J Med Virol*. doi:10.1002/jmv.26873

- Buhaescu I, Izzedine H. 2007. Mevalonate pathway: A review of clinical and therapeutical implications. *Clin Biochem* 40:575–584. doi:10.1016/j.clinbiochem.2007.03.016
- Dagliati A, Malovini A, Tibollo V, Bellazzi R. 2021. Health informatics and EHR to support clinical research in the COVID-19 pandemic: an overview. *Brief Bioinform*. doi:10.1093/bib/bbaa418
- Estiri H, Strasser ZH, Klann JG, Naseri P, Wagholikar KB, Murphy SN. 2021. Predicting COVID-19 mortality with electronic medical records. *NPJ Digit Med* **4**:15. doi:10.1038/s41746-021-00383-x
- Gower TL, Graham BS. 2001. Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro. *Antimicrob Agents Chemother* **45**:1231–1237. doi:10.1128/AAC.45.4.1231-1237.2001
- Iroegbu JD, Ifenatuoha CW, Ijomone OM. 2020. Potential neurological impact of coronaviruses: implications for the novel SARS-CoV-2. *Neurol Sci* **41**:1329–1337. doi:10.1007/s10072-020-04469-4
- Israel A, Cicurel AA, Feldhamer I, Dror Y, Giveon SM, Gillis D, Strich D, Lavie G. 2020. The link between vitamin D deficiency and Covid-19 in a large population. *medRxiv* 2020.09.04.20188268. doi:10.1101/2020.09.04.20188268
- Kim JH, Ta CN, Liu C, Sung C, Butler AM, Stewart LA, Ena L, Rogers JR, Lee J, Ostropolets A, Ryan PB, Liu H, Lee SM, Elkind MS V, Weng C. 2021. Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials. J Am Med Inform Assoc 28:14–22. doi:10.1093/jamia/ocaa276
- Koren G, Shlezinger M, Katz R, Shalev V, Amitai Y. 2017. Seawater desalination and serum magnesium concentrations in Israel. J Water Health 15:296–299. doi:10.2166/wh.2016.164
- Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, Laue M, Schneider J, Brünink S, Greuel S, Lehmann M, Hassan O, Aschman T, Schumann E, Chua RL, Conrad C, Eils R, Stenzel W, Windgassen M, Rößler L, Goebel HH, Gelderblom HR, Martin H, Nitsche A, Schulz-Schaeffer WJ, Hakroush S, Winkler MS, Tampe B, Scheibe F, Körtvélyessy P, Reinhold D, Siegmund B, Kühl AA, Elezkurtaj S, Horst D, Oesterhelweg L, Tsokos M, Ingold-Heppner B, Stadelmann C, Drosten C, Corman VM, Radbruch H, Heppner FL. 2020. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. *Nat Neurosci* 1–8. doi:10.1038/s41593-020-00758-5
- Merzon E, Tworowski D, Gorohovski A, Vinker S, Golan Cohen A, Green I, Frenkel-Morgenstern M. 2020. Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: an Israeli population-based study. *FEBS J* 287:3693–3702. doi:10.1111/febs.15495
- Morales DR, Conover MM, You SC, Pratt N, Kostka K, Duarte-Salles T, Fernández-Bertolín S, Aragón M, DuVall SL, Lynch K, Falconer T, van Bochove K, Sung C, Matheny ME, Lambert CG, Nyberg F, Alshammari TM, Williams AE, Park RW, Weaver J, Sena AG, Schuemie MJ, Rijnbeek PR, Williams RD, Lane JCE, Prats-Uribe A, Zhang L, Areia C, Krumholz HM, Prieto-Alhambra D, Ryan PB, Hripcsak G, Suchard MA. 2020. Renin–angiotensin system blockers and susceptibility to COVID-19: an international, open science, cohort analysis. *Lancet Digit Heal* **3**:98–114. doi:10.1016/s2589-7500(20)30289-2
- Osborne TF, Veigulis ZP, Arreola DM, Röösli E, Curtin CM. 2020. Automated EHR score to predict COVID-19 outcomes at US Department of Veterans Affairs. *PLoS One* **15**:e0236554. doi:10.1371/journal.pone.0236554
- Osuna-Ramos JF, Reyes-Ruiz JM, Del Ángel RM. 2018. The Role of Host Cholesterol During Flavivirus Infection. Front Cell Infect Microbiol 8:388. doi:10.3389/fcimb.2018.00388
- Qu H, Guo M, Chai H, Wang WT, Ga ZY, Shi DZ. 2018. Effects of coenzyme Q10 on statin-induced myopathy: An updated meta-analysis of randomized controlled trials. *J Am Heart Assoc* **7**:e009835. doi:10.1161/JAHA.118.009835
- Ragan I, Hartson L, Pidcoke H, Bowen R, Goodrich R. 2020. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light. *PLoS One* 15:e0233947. doi:10.1371/journal.pone.0233947
- Rossman JS, Jing X, Leser GP, Balannik V, Pinto LH, Lamb RA. 2010. Influenza Virus M2 Ion Channel Protein Is Necessary for Filamentous Virion Formation. J Virol 84:5078–5088. doi:10.1128/jvi.00119-10
- Shadmi E, Balicer RD, Kinder K, Abrams C, Weiner JP. 2011. Assessing socioeconomic health care utilization inequity in Israel: Impact of alternative approaches to morbidity adjustment, BMC Public Health.

doi:10.1186/1471-2458-11-609

- Song E, Zhang C, Israelow B, Lu-Culligan A, Prado AV, Skriabine S, Lu P, Weizman O-E, Liu F, Dai Y, Szigeti-Buck K, Yasumoto Y, Wang G, Castaldi C, Heltke J, Ng E, Wheeler J, Alfajaro MM, Levavasseur E, Fontes B, Ravindra NG, Van Dijk D, Mane S, Gunel M, Ring A, Kazmi SAJ, Zhang K, Wilen CB, Horvath TL, Plu I, Haik S, Thomas J-L, Louvi A, Farhadian SF, Huttner A, Seilhean D, Renier N, Bilguvar K, Iwasaki A. 2021. Neuroinvasion of SARS-CoV-2 in human and mouse brain. *J Exp Med* 218. doi:10.1084/jem.20202135
- Sudat SEK, Robinson SC, Mudiganti S, Mani A, Pressman AR. 2021. Mind the clinical-analytic gap: Electronic health records and COVID-19 pandemic response. J Biomed Inform 116:103715. doi:10.1016/j.jbi.2021.103715
- Sun X, Whittaker GR. 2003. Role for Influenza Virus Envelope Cholesterol in Virus Entry and Infection. *J Virol* **77**:12543–12551. doi:10.1128/jvi.77.23.12543-12551.2003
- Trasino SE. 2020. A role for retinoids in the treatment of COVID-19? *Clin Exp Pharmacol Physiol*. doi:10.1111/1440-1681.13354
- Tsoumpra MK, Muniz JR, Barnett BL, Kwaasi AA, Pilka ES, Kavanagh KL, Evdokimov A, Walter RL, Von Delft F, Ebetino FH, Oppermann U, Russell RGG, Dunford JE. 2015. The inhibition of human farnesyl pyrophosphate synthase by nitrogen-containing bisphosphonates. Elucidating the role of active site threonine 201 and tyrosine 204 residues using enzyme mutants. *Bone* 81:478–486. doi:10.1016/j.bone.2015.08.020
- Uwitonze AM, Razzaque MS. 2018. Role of magnesium in vitamin d activation and function. J Am Osteopath Assoc. doi:10.7556/jaoa.2018.037
- Wagner T, Shweta F, Murugadoss K, Awasthi S, Venkatakrishnan AJ, Bade S, Puranik A, Kang M, Pickering BW, O'Horo JC, Bauer PR, Razonable RR, Vergidis P, Temesgen Z, Rizza S, Mahmood M, Wilson WR, Challener D, Anand P, Liebers M, Doctor Z, Silvert E, Solomon H, Anand A, Barve R, Gores G, Williams AW, Morice WG, Halamka J, Badley A, Soundararajan V. 2020. Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. *Elife* 9. doi:10.7554/eLife.58227
- Wessels I, Rolles B, Rink L. 2020. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis. Front Immunol 11:1712. doi:10.3389/fimmu.2020.01712
- Whitehorn J, Nguyen CVV, Khanh LP, Kien DTH, Quyen NTH, Tran NTT, Hang NT, Truong NT, Hue Tai LT, Cam Huong NT, Nhon VT, Van Tram T, Farrar J, Wolbers M, Simmons CP, Wills B. 2015. Lovastatin for the Treatment of Adult Patients with Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial. *Clin Infect Dis* 62:468–476. doi:10.1093/cid/civ949
- Wu CI, Postema PG, Arbelo E, Behr ER, Bezzina CR, Napolitano C, Robyns T, Probst V, Schulze-Bahr E, Remme CA, Wilde AAM. 2020. SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. *Hear Rhythm* 17:1456–1462. doi:10.1016/j.hrthm.2020.03.024
- Yavuz B, Ertugrul DT. 2012. Statins and vitamin D: A hot topic that will be discussed for a long time. *Dermatoendocrinol.* doi:10.4161/derm.20188
- Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA, Kucukazman M, Dal K, Hokkaomeroglu MS, Yavuz BB, Tutal E. 2009. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: A novel pleiotropic effect of statins? *Cardiovasc Drugs Ther* 23:295–299. doi:10.1007/s10557-009-6181-8
- Zeng W, Wang X, Li J, Yang Y, Qiu X, Song P, Xu J, Wei Y. 2020. Association of dailywear of eyeglasses with susceptibility to coronavirus disease 2019 infection. *JAMA Ophthalmol* **138**:1196–1199. doi:10.1001/jamaophthalmol.2020.3906

	Cohe	ort 1	Cohort 2		
	COVID-19 hospitalized (cases)	not hospitalized (controls)	COVID-19 hospitalized (cases)	not hospitalized (controls)	
n	6,530	32,650	6,953	13,906	
Age (mean (SD))	64.6 (16.1)	64.8 (15.8)	65.7 (16.0)	65.7 (15.8)	
Gender female (%)	3,259 (49.9)	16,295 (49.9)	3,381 (48.6)	6,762 (48.6)	
Hospitalization severity (n (%))					
mild condition	3,008 (46.1)		2,676 (38.5)		
serious condition	851 (13.0)		1,043 (15.0)		
severe condition	1,621 (24.8)		1,903 (27.4)		
deceased	1,050 (16.1)		1,331 (19.1)		
Smoking status (%)					
never smoker	5,012 (76.8)	24,218 (74.2)	5,156 (74.2)	10,312 (74.2)	
past smoker	1,115 (17.1)	5,808 (17.8)	1,338 (19.2)	2,676 (19.2)	
current smoker	403 (6.2)	2,624 (8.0)	459 (6.6)	918 (6.6)	
Nb visits at primary doctor in last year (mean (SD))	8.1 (7.9)	7.9 (7.3)	8.2 (8.4)	7.5 (7.1)	
Comorbidity (%)					
Arrhythmia	887 (13.6)	4,242 (13.0)	1,278 (18.4)	2,221 (16.0)	
Asthma	527 (8.1)	2,941 (9.0)	650 (9.3)	1,376 (9.9)	
Congestive Heart Failure (CHF)	228 (3.5)	1,140 (3.5)	784 (11.3)	851 (6.1)	
Chronic Obstructive Pulmonary Disease (COPD)	148 (2.3)	740 (2.3)	603 (8.7)	776 (5.6)	
Diabetes	2,976 (45.6)	14,880 (45.6)	3,425 (49.3)	5,549 (39.9)	
Hypertension	3,850 (59.0)	19,062 (58.4)	4,396 (63.2)	8,102 (58.3)	
Ischemic Heart Disease (IHD)	1,464 (22.4)	7,320 (22.4)	1,838 (26.4)	3,113 (22.4)	
Malignancy	1,087 (16.6)	5,435 (16.6)	1,280 (18.4)	2,766 (19.9)	
Chronic Kidney Disease (CKD)	102 (1.6)	510 (1.6)	1,086 (15.6)	1,117 (8.0)	
Obesity (documented diagnosis)	3,761 (57.6)	17,837 (54.6)	3,975 (57.2)	7,950 (57.2)	
Body Mass Index (BMI) (mean (SD))	28.7 (5.7)	28.6 (6.5)	29.1 (6.3)	28.5 (5.7)	
BMI group (%)					
<18.5	17 (0.3)	85 (0.3)	51 (0.7)	93 (0.7)	
18.5-25	1,070 (16.4)	5,350 (16.4)	1,244 (17.9)	2,471 (17.8)	
A.T. A.A.	1				

2,295 (35.1)

2,053 (31.4)

761 (11.7)

334 (5.1)

85.7 (21.6)

11,475 (35.1)

10,265 (31.4)

3,805 (11.7)

1,670 (5.1)

85.8 (20.3)

25-30

30-35

35-40

Glomerular Filtration Rate

>40

Table 1: Demographics and clinical characteristics of the two matched cohorts of patients (hospitalized vs. non-hospitalized)

4,870 (35.0)

4,267 (30.7)

1,562 (11.2)

643 (4.6)

83.4 (22.4)

2,264 (32.6)

2,005 (28.8)

886 (12.7)

503 (7.2)

78.7 (28.2)

(GFR) (mean (SD))				
Chronic Kidney Disease				
(CKD) staging (n (%))				
G1	3,047 (46.7)	15,145 (46.4)	2,837 (40.8)	6,090 (43.8)
G2	2,679 (41.0)	13,747 (42.1)	2,535 (36.5)	5,722 (41.1)
G3a	558 (8.5)	2,817 (8.6)	689 (9.9)	1,257 (9.0)
G3b	203 (3.1)	836 (2.6)	391 (5.6)	571 (4.1)
G4	41 (0.6)	89 (0.3)	186 (2.7)	160 (1.2)
G5			63 (0.9)	28 (0.2)
Dialysis	2 (0.0)	16 (0.0)	252 (3.6)	78 (0.6)

Table 2: Most significant associations for medications acquired in the 35 days preceding the index date in two matched cohorts

ATC code and class	use in case	use in contr.	case %	contr. %	odds ratio (95% Conf. Int.)	P-value	FDR
C10AA07	328	2380	5.02	7.29	0.673 (0.596 to 0.758)	< 0.0001	< 0.001
Rosuvastatin C10AX09							
Ezetimibe	73	740	1.12	2.27	0.488 (0.377 to 0.622)	< 0.0001	< 0.001
A16AX30 Ubiquinone (CoQ-10)	6	165	0.09	0.51	0.181 (0.065 to 0.403)	< 0.0001	< 0.001
C01BC04 Flecainide	7	116	0.11	0.36	0.301 (0.118 to 0.641)	0.00039	0.005
J07AL02 Pneumococcus	21	220	0.32	0.67	0.476 (0.288 to 0.746)	0.00049	0.006
vaccine conjugate C09BA05 Ramipril-	127	859	1.95	2.63	0.734 (0.603 to 0.887)	0.00099	0.011
Hydrochlorothiazide A10BD07							
Sitagliptin-Metformin	243	1501	3.72	4.60	0.802 (0.696 to 0.922)	0.00159	0.017
C10AA03 Pravastatin	52	385	0.80	1.18	0.673 (0.493 to 0.902)	0.00659	0.060
N06AB10 Escitalopram	216	1302	3.31	3.99	0.824 (0.708 to 0.955)	0.00930	0.078
M01AC01 Piroxicam	24	205	0.37	0.63	0.584 (0.365 to 0.894)	0.00980	0.082
C09CA06	65	451	1.00	1.38	0.718 (0.544 to 0.934)	0.01237	0.100
Candesartan M05BA07							
Risedronic Acid	56	396	0.86	1.21	0.705 (0.522 to 0.935)	0.01319	0.103
G04CB02 Dutasteride	30	240	0.46	0.74	0.623 (0.411 to 0.914)	0.01367	0.105
A11CC05 Cholecalciferol	660	3634	10.11	11.13	0.898 (0.821 to 0.980)	0.01600	0.119
C09AA08 Cilazapril	17	153	0.26	0.47	0.554 (0.315 to 0.918)	0.01743	0.124
G04BE08 Tadalafil	29	229	0.44	0.70	0.632 (0.413 to 0.933)	0.01862	0.132
S01ED61 Timolol-Travoprost	8	90	0.12	0.28	0.444 (0.186 to 0.913)	0.02068	0.142
A10BH01 Sitagliptin	33	250	0.51	0.77	0.658 (0.443 to 0.950)	0.02461	0.162
J07BB02	392	2205	6.00	6.75	0.882 (0.787 to 0.986)	0.02548	0.165
Influenza vaccine inac N06DX02 Cipluga folium	2	42	0.03	0.13	0.238 (0.028 to 0.915)	0.02552	0.165
Ginkgo folium A12CC04	31	237	0.48	0.73	0.652 (0.433 to 0.952)	0.02597	0.166
Magnesium Citrate A10BK01 Dapagliflozin	35	255	0.54	0.78	0.685 (0.466 to 0.978)	0.03283	0.193

A. Cohort 1 ($N = 6,530$ hospitalization cases,	N=32,650 controls taken	from the general p	opulation)
--	-------------------------	--------------------	------------

B. Cohort 2 (N = 6,953 hospitalization cases, N=13,906 controls taken from patients SARS-CoV-2

positive)

ATC code and class	use in case	use in contr.	case %	contr. %	odds ratio (95% Conf. Int.)	P-value	FDR
C10AA07	354	950	5.09	6.83	0.732 (0.643 to 0.831)	< 0.0001	0.000
Rosuvastatin			,				
C10AX09 Ezetimibe	92	303	1.32	2.18	0.602 (0.471 to 0.764)	0.00001	0.000
J07AL02 Pneumococcus	20	95	0.29	0.68	0.419 (0.245 to 0.685)	0.00021	0.003
vaccine conjugate			0.22	0.00		0.00021	0.000
M05BA07 Risedronic Acid	47	165	0.68	1.19	0.567 (0.400 to 0.789)	0.00042	0.005
A16AX30	9	56	0.13	0.40	0.321 (0.139 to 0.653)	0.00052	0.006
Ubiquinone (CoQ-10) N06AB10	226	(10	2 20	4.20	0.766 (0.654 += 0.804)	0.000/1	0.007
Escitalopram	236	610	3.39	4.39	0.766 (0.654 to 0.894)	0.00061	0.007
C09BA05 Ramipril- Hydrochlorothiazide	121	342	1.74	2.46	0.702 (0.565 to 0.869)	0.00082	0.009
C01BC04	7	43	0.10	0.31	0.325 (0.123 to 0.729)	0.00253	0.023
Flecainide		-			(
S01XA40 Hydroxypropyl- methylcellulose (tears)	67	203	0.96	1.46	0.657 (0.490 to 0.871)	0.00273	0.025
A11CC05 Cholecalciferol	737	1669	10.60	12.00	0.869 (0.792 to 0.954)	0.00280	0.025
B01AE07	27	124	0.52	0.90	0.505 (0.400 +- 0.966)	0.005.42	0.042
Dabigatran Etexilate	37	124	0.53	0.89	0.595 (0.400 to 0.866)	0.00543	0.042
C09AA08 Cilazapril	15	64	0.22	0.46	0.468 (0.247 to 0.831)	0.00579	0.044
N02CC04	1	17	0.01	0.12	0.118 (0.003 to 0.750)	0.01065	0.075
Rizatriptan	1	17	0.01	0.12	0.118 (0.003 to 0.750)	0.01005	0.075
A12CC04 Magnesium Citrate	33	108	0.48	0.78	0.609 (0.399 to 0.908)	0.01191	0.080
S01KA01 Hyaluronic	5	21	0.07	0.22	0.222 (0.000 +- 0.026)	0.01240	0.092
Acid (artificial tears)	5	31	0.07	0.22	0.322 (0.098 to 0.836)	0.01249	0.083
C09DB01 Valsartan-Amlodipine	227	549	3.27	3.95	0.821 (0.698 to 0.963)	0.01445	0.094
A10BD07	233	560	3.35	4.03	0.826 (0.704 to 0.967)	0.01721	0.108
Sitagliptin-Metformin B03BA51	31	100	0.45	0.72	$0.618(0.200 \pm 0.024)$	0.01070	0.119
Vit.B12 combinations	51	100	0.45	0.72	0.618 (0.399 to 0.934)	0.01979	0.119
G03CA03 Estradiol	18	67	0.26	0.48	0.536 (0.300 to 0.914)	0.02047	0.122
C09DA01 Losartan- Hydrochlorothiazide	124	315	1.78	2.27	0.783 (0.630 to 0.969)	0.02424	0.140
S01ED01	20	70	0.29	0.50	0.570 (0.328 to 0.949)	0.02492	0.143
Timolol G04BD12		,0	0.27			0.02772	0.175
G04BD12 Mirabegron	22	74	0.32	0.53	0.593 (0.351 to 0.967)	0.02998	0.163
S01XA02 Retinol (eye ointment)	3	21	0.04	0.15	0.285 (0.054 to 0.956)	0.03015	0.163
Z01CE01	3	21	0.04	0.15	0.285 (0.054 to 0.956)	0.03015	0.163
Eye Care Wipes	5	<i>2</i> 1	0.04	0.15	0.205 (0.054 10 0.750)	0.03013	0.105


N06AX12 Bupropion	6	30	0.09	0.22	0.399 (0.136 to 0.976)	0.03385	0.177
N06BA04 Methylphenidate	8	36	0.12	0.26	0.444 (0.178 to 0.972)	0.03656	0.186
A12AX05 Calcium-Zinc CD	0	10	0.00	0.07	0.000 (0.000 to 0.892)	0.03696	0.186
A11JC02 Multivitamins for Ocular Use	25	81	0.36	0.58	0.616 (0.376 to 0.976)	0.03827	0.191


Numbers are of patients from the group who have acquired a medication from the class in the last month before the index date.

P-values are calculated according to Fisher's exact test. Medications are sorted by increasing order of p-values.

OR: Odds ratio; [95% CI]: 95% Confidence Interval; FDR: False Discovery Rate calculated according to Benjamini-Hochberg (BH) procedure.


Are shown in this table ATC classes for which the p-value is less than 0.05, and for which the FDR is less than 0.20 (about 80% of entries are expected to be true positive).





The overwhelming majority of medications are associated with neutral effect (gray) or increased risk for hospitalization (black, OR>1), only a few are associated with significantly decreased risk (black, OR<1)





Ubiquinone and cholesterol biosynthesis pathways originate from a branching of the mevalonate pathway at FPP. Rosuvastatin and other statins can inhibit the HMG-CoA reductase, while risedronic acid and other bisphosphonates can inhibit the FPP synthase. Ac-CoA: acetyl coenzyme A, HMG-CoA: hydroxymethylglutaryl coenzyme A, GPP: geranyl pyrophosphate, FPP: farnesyl pyrophosphate, PPP: polyprenyl pyrophosphate.